Micronized Progesterone: Dosing, Routes, Contraindications, and Monitoring
For prevention of recurrent preterm birth in singleton pregnancies with prior spontaneous preterm birth, 17-alpha hydroxyprogesterone caproate (17OHP-C) 250 mg intramuscularly weekly is the preferred progestogen, not micronized progesterone. 1
Prevention of Recurrent Preterm Birth
Recommended Agent and Dosing
- 17OHP-C 250 mg intramuscularly weekly is the standard of care for women with singleton pregnancy and prior spontaneous preterm birth at 20-36 6/7 weeks 1
- Initiate between 16-20 weeks of gestation and continue until 36 weeks of gestation 1
- This recommendation is based on a 34% reduction in recurrent preterm birth (from 54.9% to 36.3%) demonstrated in the pivotal Meis trial 1
Why Not Micronized Progesterone for This Indication?
- Vaginal micronized progesterone (90-200 mg daily) failed to demonstrate efficacy in multiple high-quality trials for women with prior spontaneous preterm birth 1
- The O'Brien trial (659 women) showed no difference in preterm birth rates at <32 weeks (10.0% vs 11.3%) or <37 weeks (41.7% vs 40.7%) with vaginal progesterone versus placebo 1
- The OPPTIMUM study (903 women with prior preterm birth) found no significant differences in preterm birth at <34 weeks (15.9% vs 18.8%) with vaginal progesterone versus placebo 1
- The Society for Maternal-Fetal Medicine explicitly revised its 2012 guidance away from vaginal progesterone for this indication based on this evidence 1
Luteal Phase Support After In Vitro Fertilization
Dosing Regimens and Routes
Vaginal Route (Preferred for High Responders):
- Micronized progesterone 100 mg twice daily (200 mg/day) vaginally is effective and well-tolerated 2
- This low-dose vaginal regimen achieved a 30.7% implantation rate and 47% clinical pregnancy rate in high responders 2
- Particularly recommended for patients at risk of ovarian hyperstimulation syndrome due to lower systemic absorption 2
Oral Route:
- Micronized progesterone 400 mg daily orally demonstrated non-inferiority to vaginal progesterone 90 mg daily for ongoing pregnancy rates (35.3% vs 38.0%) 3
- Start on day of oocyte retrieval and continue until 11-12 weeks of gestation 3
- The 600 mg daily oral dose did NOT demonstrate non-inferiority and may be associated with poorer outcomes 3
Combined Regimens:
- Vaginal micronized progesterone 400 mg twice daily PLUS oral dydrogesterone 10 mg twice daily showed superior outcomes in frozen embryo transfer cycles 4
- This combination achieved a 46.3% live birth rate versus 41.3% with vaginal progesterone alone (adjusted RR 1.30, P=0.042) 4
- Miscarriage rate was significantly lower with combination therapy (3.4% vs 6.6%, P=0.009) 4
Pharmacokinetic Considerations
- Oral micronized progesterone shows rapid clearance with Tmax of 1.5-1.6 hours, necessitating multiple daily doses 5
- Vaginal progesterone has delayed absorption with Tmax of 4.2-7.3 hours, providing more sustained levels 5
- Administration frequency is critical for oral formulations due to rapid metabolism 5
Monitoring
- No routine progesterone level monitoring is required as endometrial transformation is the therapeutic target, not serum levels 6, 5
- Pregnancy testing typically performed 10-14 days after embryo transfer 3
- Continue luteal support until 11-12 weeks of gestation in conception cycles 3
Menopausal Hormone Therapy
Dosing for Endometrial Protection
For Women with Intact Uterus (Essential to Prevent Endometrial Cancer):
Cyclic Regimens:
- Micronized progesterone 200 mg orally daily for 12-14 days per month when combined with estrogen 7, 8
- This regimen reduces endometrial hyperplasia and cancer risk associated with unopposed estrogen 7
- Administer at bedtime to minimize transient drowsiness 9
Continuous Combined Regimens:
- Micronized progesterone 100 mg orally daily for 25 days per month for women desiring amenorrhea 9
- Continuous combined conjugated estrogens with medroxyprogesterone acetate reduced endometrial cancer risk over 13 years of follow-up 7
Critical Safety Considerations
Endometrial Cancer Risk:
- Unopposed estrogen dramatically increases endometrial cancer risk (relative risk 2.1-5.7) 9
- Concurrent progestogen for at least 12 days per month is mandatory for all women with a uterus 7
- Micronized progesterone and dydrogesterone used beyond 5 years showed approximately 2-fold increased endometrial cancer risk in observational studies 7
- Sequential regimens beyond 6-10 years may carry 2-fold increased risk, particularly in thin women 7
Breast Cancer Considerations:
- Most observational studies report increased breast cancer risk with oral or transdermal estradiol as a function of duration 7
- Risk increases linearly with treatment duration 7
Available Formulations
- 100 mg and 200 mg capsules are FDA-approved formulations 8
- Store at 25°C (77°F) with excursions permitted to 15-30°C 8
- Contains peanut oil - contraindicated in peanut allergy 8
Adverse Effects in Menopausal Women
Common adverse reactions (≥2%) with progesterone 200 mg + conjugated estrogens 0.625 mg include 8:
- Headache (31%)
- Breast tenderness (27%)
- Joint pain (20%)
- Depression (19%)
- Dizziness (15%)
- Abdominal bloating (12%)
Serious Adverse Events:
- Extreme dizziness/drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness may occur during initial therapy 8
- Hepatic complications including cholestatic hepatitis, hepatic failure, and hepatic necrosis have been reported 8
- Cardiovascular events including circulatory collapse, hypertension, and transient ischemic attack 8
Contraindications (Absolute)
- Peanut allergy (formulation contains peanut oil) 8
- Known or suspected breast cancer 7
- Known or suspected estrogen-dependent neoplasia 7
- Active or history of venous thromboembolism 7
- Active arterial thromboembolic disease 7
- Liver dysfunction or disease 8
- Undiagnosed abnormal uterine bleeding 7
Monitoring Requirements
- Endometrial assessment if breakthrough bleeding occurs on continuous regimens 7
- Annual breast examination and mammography as per standard guidelines 7
- Liver function tests if symptoms of hepatic dysfunction develop 8
- Reassess need for continued therapy annually, using lowest effective dose 7
Key Clinical Pitfalls to Avoid
Never use unopposed estrogen in women with a uterus - this is the most critical error, dramatically increasing endometrial cancer risk 7, 9
Do not use vaginal micronized progesterone for prevention of recurrent preterm birth - multiple trials show lack of efficacy; use 17OHP-C instead 1
Do not exceed 400 mg daily oral dose for IVF luteal support - the 600 mg dose failed to demonstrate non-inferiority and may worsen outcomes 3
Screen for peanut allergy before prescribing - micronized progesterone capsules contain peanut oil 8
Warn patients about initial neurological symptoms - extreme dizziness, drowsiness, and coordination problems can occur; recommend bedtime dosing 8, 9
Do not rely on serum progesterone levels to guide luteal support - endometrial response is the target, not serum concentrations 6, 5